These findings demonstrate the importance of BRCA1/2 mutation testing in breast cancer patients, as identifying BRCA1/2 mutations can lead to personalized treatment decisions, such as the use of targeted therapies like olaparib, which have shown significant benefits in reducing the risk of recurrence and improving survival rates in patients with BRCA1/2 mutations. This evidence concerns the gene BRCA1 and breast cancer.